Haemonetics Corporation HAE R2K
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Generates positive free cash flow.
CONS
- Earnings shrank at -5.5% CAGR over 5 years.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | HAE Haemonetics Corporation R2K | 67.81 | 33.08 | $3.08B | - | 7.42% | 12.03% | 4.51% | -5.53% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Apr 2016 | Jul 2016 | Oct 2016 | Dec 2016 | Apr 2017 | Jul 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Apr 2021 | Jul 2021 | Oct 2021 | Jan 2022 | Jul 2022 | Oct 2022 | Dec 2022 | Jul 2023 | Sep 2023 | Dec 2023 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 210.95M | 225.38M | 234.04M | - | 229.35M | 241.58M | 247.36M | - | 238.45M | 252.57M | 258.97M | - | 195.58M | 209.49M | 240.37M | - | 228.53M | 239.90M | 259.77M | 261.46M | 297.49M | 305.30M | 311.33M | 318.18M | 336.25M | 336.17M | 345.51M | - | 330.60M | 321.39M | 327.31M | 338.97M | 346.35M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 137.55M | 129.15M | 132.57M | 136.58M | 148.14M |
| Gross Profit | 105.30M | 108.86M | 89.22M | 91.06M | 104.25M | 101.08M | 82.11M | 91.67M | 104.56M | 111.30M | 104.39M | 83.24M | 111.91M | 111.17M | 111.21M | 115.91M | 127.00M | 128.05M | 113.56M | 90.03M | 105.74M | 120.26M | 81.81M | 108.08M | 122.54M | 138.56M | 142.26M | 157.88M | 158.71M | 167.26M | 170.51M | 177.87M | 174.92M | 187.44M | - | 193.05M | 192.24M | 194.74M | 202.39M | 198.21M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 142.35M | 138.37M | 127.67M | 134.27M | 145.87M |
| Operating Income | 19.18M | -61.18M | -5.55M | -7.88M | 24.79M | 21.21M | -57.51M | 16.61M | 24.26M | 1.01M | 14.28M | 5.29M | 26.08M | 28.32M | 23.86M | -13.30M | 49.74M | 40.91M | 26.01M | 11.71M | 58.78M | 40.42M | -21.18M | 1.39M | 24.51M | 35.65M | 30.77M | 46.73M | 43.28M | 53.66M | 35.30M | 45.98M | 39.76M | 51.70M | - | 50.70M | 53.87M | 67.08M | 68.11M | 52.34M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 99.54M | 82.63M | 86.75M | 94.78M | 4.29M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 598.00K | 8.70M | 7.21M | 7.42M | 5.37M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 70.74M | 45.17M | 51.28M | 59.98M | -28.40M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.76M | 11.14M | 12.60M | 15.23M | -8.25M |
| Net Income | 12.86M | -59.44M | -8.73M | -10.35M | 19.82M | 15.39M | -51.14M | 20.14M | 20.10M | -6.55M | 11.88M | -2.82M | 18.73M | -8.48M | 20.84M | -8.48M | 37.49M | 29.89M | 17.62M | 10.53M | 48.10M | 31.88M | -11.04M | -4.45M | 14.86M | 23.23M | 19.88M | 33.20M | 32.94M | 41.04M | 24.91M | 31.24M | 38.37M | 33.83M | - | 57.98M | 34.03M | 38.68M | 44.74M | -20.15M |
| Diluted EPS | 0.25 | -1.17 | -0.17 | -0.20 | 0.38 | 0.30 | -0.98 | 0.38 | 0.38 | -0.12 | 0.22 | -0.05 | 0.35 | 0.35 | 0.40 | -0.17 | 0.72 | 0.58 | 0.34 | 0.21 | 0.94 | 0.62 | -0.22 | -0.09 | 0.29 | 0.45 | 0.38 | 0.64 | 0.64 | 0.80 | 0.48 | 0.61 | 0.74 | 0.66 | 0.74 | 1.17 | 0.70 | 0.81 | 0.95 | - |
| R&D Expense | 11.55M | 10.94M | - | 11.44M | 8.34M | 8.46M | - | 8.19M | 7.52M | 12.43M | - | 9.41M | 8.58M | 8.98M | - | 7.49M | 7.42M | 7.00M | - | 7.75M | 6.76M | 7.50M | - | 12.70M | 10.85M | 10.04M | 10.90M | 10.90M | 12.69M | 12.65M | 12.66M | 13.27M | 14.45M | 14.14M | 15.83M | - | 16.26M | 14.87M | 14.19M | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2009 | Apr 2010 | Apr 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Apr 2016 | Apr 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Apr 2021 | Mar 2022 | Apr 2022 | Mar 2023 | Apr 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 993.20M | 1.17B | 1.17B | 1.31B | 1.36B | 1.33B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 553.56M | - | 617.51M | 611.87M | 546.44M |
| Gross Profit | 308.17M | 337.48M | 355.21M | 369.24M | 428.13M | 468.37M | 434.42M | 405.91M | 378.49M | 411.91M | 417.54M | 484.51M | 397.84M | - | 505.50M | 615.10M | 615.10M | 691.55M | 748.96M | 787.59M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 459.45M | - | 516.25M | 547.77M | 546.18M |
| Operating Income | 85.57M | 83.28M | 110.55M | 88.76M | 56.44M | 46.43M | 40.54M | -43.94M | -19.38M | 56.16M | 83.55M | 103.35M | 89.75M | - | 80.75M | 155.65M | 156.03M | 175.30M | 201.19M | 241.40M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 249.34M | - | 262.10M | 337.40M | 268.45M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.63M | - | 13.02M | 9.75M | 28.70M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 141.40M | - | 151.87M | 212.07M | 128.03M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 26.00M | - | 34.31M | 44.39M | 30.72M |
| Net Income | 59.30M | 58.37M | 79.98M | 66.89M | 38.80M | 35.15M | 16.90M | -55.58M | -26.27M | 45.57M | 55.02M | 76.53M | 79.47M | - | 43.38M | 115.40M | 115.40M | 117.56M | 167.68M | 97.31M |
| Diluted EPS | 2.27 | 2.24 | 1.56 | 1.30 | 0.74 | 0.67 | 0.32 | -1.09 | -0.51 | 0.85 | 1.04 | 1.48 | 1.55 | 0.84 | 0.84 | 2.24 | 2.24 | 2.29 | 3.31 | - |
| R&D Expense | 23.86M | 26.38M | 32.66M | 36.80M | 44.39M | 54.20M | 54.19M | 44.97M | 37.56M | 39.23M | 35.71M | 30.88M | 32.86M | - | 46.80M | - | 50.13M | 54.44M | 62.72M | 59.77M |
Compounded Sales Growth
| 5 Years: | 4.51% |
| 1 Year: | 4.80% |
Compounded Profit Growth
| 5 Years: | -5.53% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +0.15% |
| 6 Months: | -15.90% |
| 3 Months: | +7.09% |
| 1 Month: | +14.91% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2008 | Mar 2009 | Apr 2010 | Apr 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Apr 2016 | Apr 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Apr 2021 | Mar 2022 | Apr 2022 | Mar 2023 | Apr 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 764.30M | 833.26M | 911.13M | 1.46B | 1.51B | 1.49B | 1.32B | 1.24B | 1.24B | 1.27B | 1.27B | 1.82B | - | 1.86B | 1.93B | 1.93B | 2.20B | 2.45B | 2.40B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 769.72M | - | 768.90M | 934.98M | 834.88M |
| Cash & Equivalents | 133.55M | 156.72M | 141.56M | 196.71M | 228.86M | 179.12M | 192.47M | 160.66M | 115.12M | 139.56M | 180.17M | 169.35M | 137.31M | 192.31M | - | 259.50M | 284.47M | 284.47M | 178.80M | 306.76M | 245.44M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 259.38M | - | 317.20M | 365.14M | 306.37M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 179.14M | - | 206.56M | 202.66M | 216.85M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.12B | - | 1.24B | 1.63B | 1.60B |
| Current Liabilities | - | - | 135.05M | 108.67M | 130.74M | 180.14M | 216.93M | 188.68M | 185.55M | 211.18M | 384.70M | 235.76M | 274.82M | 253.50M | - | 442.27M | 251.82M | 251.82M | 300.38M | 578.11M | 282.60M |
| Long Term Debt | - | - | 4.46M | 3.97M | 2.88M | 456.94M | 392.06M | 406.37M | 364.53M | 253.62M | 59.42M | 322.45M | 305.51M | 690.59M | - | 559.44M | 754.10M | 754.10M | 797.56M | 921.23M | 1.22B |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 765.89M | - | 807.79M | 1.22B | 1.22B |
| Total Equity | 494.19M | 539.88M | 593.12M | 686.14M | 732.63M | 769.18M | 837.89M | 826.12M | 721.57M | 739.61M | 752.43M | 667.87M | 587.11M | 731.67M | - | 749.42M | 818.00M | 818.00M | 959.96M | 820.84M | 796.32M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 50.45M | - | 50.79M | 48.22M | 45.25M |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2009 | Apr 2010 | Apr 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Apr 2016 | Apr 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Apr 2021 | Mar 2022 | Apr 2022 | Mar 2023 | Apr 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 116.36M | 130.67M | 123.45M | 115.32M | 85.07M | 139.52M | 127.18M | 121.86M | 159.74M | 220.35M | 159.28M | 158.22M | 108.81M | - | 172.26M | 273.06M | 273.06M | 181.75M | 181.72M | 293.22M |
| Investing Cash Flow | -60.00M | -132.34M | -51.56M | -52.20M | -596.39M | -105.83M | -121.77M | -104.77M | -73.31M | -63.04M | -116.15M | -57.18M | -425.44M | - | -86.34M | -143.79M | -143.79M | -322.39M | -161.90M | -179.55M |
| Financing Cash Flow | -30.74M | -13.97M | -18.08M | -30.47M | 461.85M | -20.70M | -33.16M | -62.62M | -60.41M | -120.64M | -50.63M | -131.21M | 367.45M | - | -15.75M | -100.36M | -100.36M | 38.16M | 108.82M | -178.46M |
| Capital Expenditure | -56.38M | -56.30M | -46.67M | -53.20M | -62.19M | -73.65M | -122.22M | -102.41M | -76.14M | -74.80M | -118.96M | -48.76M | -37.04M | - | -96.51M | -191.33M | -191.33M | -38.12M | -39.28M | -32.78M |
| Free Cash Flow | 59.98M | 74.36M | 76.79M | 62.12M | 22.89M | 65.88M | 4.96M | 19.46M | 83.60M | 145.55M | 40.32M | 109.46M | 71.77M | - | 75.75M | 81.73M | 81.73M | 143.63M | 142.45M | 260.44M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 28.91M | - | -102.48M | 128.65M | -64.79M |
| Share Buybacks | 60.00M | 40.00M | 50.00M | 50.00M | 50.00M | 0 | 39.03M | 60.98M | 0 | 100.00M | 160.00M | 175.00M | 0 | - | 0 | - | 75.00M | 0 | 225.00M | 175.00M |
Ratios (Annual)
Figures in %.
| Metric | Mar 2009 | Apr 2010 | Apr 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Apr 2016 | Apr 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Apr 2021 | Mar 2022 | Apr 2022 | Mar 2023 | Apr 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 50.9% | 52.6% | 52.6% | 52.8% | 55.0% | 59.0% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.1% | 13.3% | 13.4% | 13.4% | 14.8% | 18.1% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.4% | 9.9% | 9.9% | 9.0% | 12.3% | 7.3% |
| ROE % | 11.0% | 9.8% | 11.7% | 9.1% | 5.0% | 4.2% | 2.0% | -7.7% | -3.6% | 6.1% | 8.2% | 13.0% | 10.9% | - | 5.8% | 14.1% | 14.1% | 12.2% | 20.4% | 12.2% |
| ROCE % | - | 13.2% | 15.3% | 11.4% | 4.4% | 3.6% | 3.1% | -3.9% | -1.9% | 6.6% | 8.0% | 10.4% | 5.7% | - | 5.7% | 9.2% | 9.3% | 9.2% | 10.7% | 11.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 12.37% | 5.62M | $381.09M |
| 2 | Neuberger Berman Group, LLC | 7.84% | 3.56M | $241.47M |
| 3 | AQR Capital Management, LLC | 7.39% | 3.36M | $227.61M |
| 4 | Vanguard Portfolio Management LLC | 5.63% | 2.56M | $173.55M |
| 5 | Vanguard Capital Management LLC | 4.60% | 2.09M | $141.75M |
| 6 | State Street Corporation | 3.90% | 1.77M | $120.22M |
| 7 | Arrowstreet Capital, Limited Partnership | 3.04% | 1.38M | $93.78M |
| 8 | River Road Asset Management, LLC | 2.92% | 1.33M | $90.05M |
| 9 | Dimensional Fund Advisors LP | 2.92% | 1.33M | $89.92M |
| 10 | FMR, LLC | 2.81% | 1.28M | $86.52M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HAE